{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:27:47Z","timestamp":1794587267147,"version":"4.9.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Hydrochlorothiazide (HCTZ) is commonly prescribed to cancer patients. However, there is a paucity of research examining the effects of HCTZ exposure on the mortality risk of cancer survivors. We constructed a prospective cohort using data from the National Health and Nutrition Examination Survey from 2003 to 2018 to investigate the associations between HCTZ exposure and the risk of all-cause mortality among cancer survivors. The participants were categorized into 2 groups based on their self-reported use of HCTZ. Multivariate-adjusted Cox proportional hazards models were used to assess the survival outcomes between groups. Multivariate-adjusted logistic regression models were conducted to investigate the association between HCTZ exposure and the risk of cardiovascular disease and cerebrovascular disease. The final cohort comprised 4202 cancer survivors, with a mean age (standard deviation) of 66.01\u2005\u00b1\u200514.35 years. Of these, 53.2% were females, and 68.4% were non-Hispanic White individuals. The medication stratification identified 3517 non-HCTZ-exposed individuals and 685 HCTZ-exposed individuals. During a mean follow-up of 6.93 years (maximum 17 years), 1337 deaths were recorded. Compared with non-HCTZ-exposed individuals, HCTZ-exposed individuals presented reduced risk of all-cause mortality (hazard ratio\u2005=\u20050.80, 95% confidence interval [CI]\u2005=\u20050.67\u20130.95;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.003). Cross-sectional studies have indicated that exposure to HCTZ is associated with a lower risk of angina pectoris (odds ratio\u2005=\u20050.81, 95% CI\u2005=\u20050.72\u20130.93;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001) and heart attack (odds ratio\u2005=\u20050.89, 95% CI\u2005=\u20050.84\u20130.95;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.001). HCTZ exposure is likely correlated with a lower risk of all-cause mortality in cancer survivors. However, HCTZ use among participants was assessed only once via self-report, lacking detailed information on dosage, duration of use, indication, cancer stage, and treatment regimens, precluding definitive conclusions regarding a protective effect of HCTZ. Further research is warranted to confirm these findings.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049430","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:00:34Z","timestamp":1782108034000},"page":"e49430","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Association of hydrochlorothiazide exposure with all-cause mortality among US cancer survivors: A prospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0789-6962","authenticated-orcid":false,"given":"Qiang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Nanyang Nanshi Hospital, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Hong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanyang Nanshi Hospital, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Hao","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanyang Nanshi Hospital, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanyang Nanshi Hospital, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanyang Nanshi Hospital, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hua","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanyang Nanshi Hospital, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Burn, Nanyang Nanshi Hospital, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Cai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, Nanyang Nanshi Hospital, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Yu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Burn, Nanyang Nanshi Hospital, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hospital Administration Office, Nanyang Nanshi Hospital, Nanyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4422-5869","authenticated-orcid":false,"given":"Jiang-Xia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanyang Nanshi Hospital, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261113","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"15_suppl","key":"R2-20261113","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.2018.36.15_suppl.1568","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: a systematic analysis for the Global Burden of Disease study.","volume":"36","author":"Fitzmaurice","year":"2018","journal-title":"JCO"},{"key":"R3-20261113","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer.","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"R4-20261113","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review.","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"R5-20261113","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.23.01367","article-title":"Survival trends among adolescents and young adults diagnosed with cancer in the United States: comparisons with children and older adults.","volume":"42","author":"Keegan","year":"2024","journal-title":"J Clin Oncol"},{"key":"R6-20261113","first-page":"337","article-title":"The impact of comorbidity on cancer and its treatment.","volume":"66","author":"Sarfati","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"R7-20261113","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41571-019-0249-6","article-title":"Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms.","volume":"16","author":"Renzi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R8-20261113","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2010.31.3049","article-title":"Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review.","volume":"29","author":"Lee","year":"2011","journal-title":"J Clin Oncol"},{"key":"R9-20261113","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ctrv.2018.02.003","article-title":"Impact of comorbidity and frailty on prognosis in colorectal cancer patients: a systematic review and meta-analysis.","volume":"64","author":"Boakye","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"R10-20261113","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41416-020-0950-3","article-title":"Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication.","volume":"123","author":"Loeppenthin","year":"2020","journal-title":"Br J Cancer"},{"key":"R11-20261113","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jgo.2022.02.006","article-title":"The prevalence and factors associated with potentially inappropriate medication use in Chinese older outpatients with cancer with multimorbidity.","volume":"13","author":"Tian","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"R12-20261113","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/HJH.0000000000002088","article-title":"Redefining diuretics use in hypertension: why select a thiazide-like diuretic?","volume":"37","author":"Burnier","year":"2019","journal-title":"J Hypertens"},{"key":"R13-20261113","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.ajkd.2021.09.029","article-title":"Diuretics in states of volume overload: core curriculum 2022.","volume":"80","author":"Novak","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"R14-20261113","doi-asserted-by":"crossref","first-page":"112855","DOI":"10.1016\/j.ejmech.2020.112855","article-title":"Modern trends in diuretics development.","volume":"208","author":"Titko","year":"2020","journal-title":"Eur J Med Chem"},{"key":"R15-20261113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2017.01.016","article-title":"Use, misuse and abuse of diuretics.","volume":"39","author":"Bartoli","year":"2017","journal-title":"Eur J Intern Med"},{"key":"R16-20261113","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1053\/j.ajkd.2019.07.011","article-title":"Thiazide-associated hyponatremia: clinical manifestations and pathophysiology.","volume":"75","author":"Filippone","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"R17-20261113","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark.","volume":"78","author":"Pedersen","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R18-20261113","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12916-022-02419-9","article-title":"Associations of thiazide use with skin cancers: a systematic review and meta-analysis.","volume":"20","author":"Shao","year":"2022","journal-title":"BMC Med"},{"key":"R19-20261113","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2023.04.035","article-title":"Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: a multisite population-based cohort study.","volume":"89","author":"Azoulay","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R20-20261113","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000517020","article-title":"The forgotten antiproteinuric properties of diuretics.","volume":"52","author":"Trujillo","year":"2021","journal-title":"Am J Nephrol"},{"key":"R21-20261113","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R22-20261113","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.jhh.1002075","article-title":"Hypertension, diuretics and breast cancer risk.","volume":"20","author":"Largent","year":"2006","journal-title":"J Hum Hypertens"},{"key":"R23-20261113","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41416-019-0613-4","article-title":"Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study.","volume":"121","author":"Potteg\u00e5rd","year":"2019","journal-title":"Br J Cancer"},{"key":"R24-20261113","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/HJH.0000000000003414","article-title":"Association of hydrochlorothiazide treatment compared with alternative diuretics with overall and skin cancer risk: a propensity-matched cohort study.","volume":"41","author":"G\u00f6tzinger","year":"2023","journal-title":"J Hypertens"},{"key":"R25-20261113","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra0907219","article-title":"Use of diuretics in patients with hypertension.","volume":"361","author":"Ernst","year":"2009","journal-title":"N Engl J Med"},{"key":"R26-20261113","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1161\/01.HYP.32.6.1071","article-title":"Thiazide-induced vasodilation in humans is mediated by potassium channel activation.","volume":"32","author":"Pickkers","year":"1998","journal-title":"Hypertension"},{"key":"R27-20261113","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.CIR.24.5.1197","article-title":"Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension.","volume":"24","author":"Gifford","year":"1961","journal-title":"Circulation"},{"key":"R28-20261113","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/01.CIR.20.6.1028","article-title":"Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide.","volume":"20","author":"Wilson","year":"1959","journal-title":"Circulation"},{"key":"R29-20261113","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/jama.1987.03390110060027","article-title":"Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial--the Hypertension Control Program.","volume":"257","author":"Stamler","year":"1987","journal-title":"JAMA"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:00:45Z","timestamp":1794585645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":29,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049430","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2025-10-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}